Moreover, EGFR-positive NSCLC and probably ROS1-rearranged NSCLC are associated with improved prognosis [16, 17], whereas this is appears not to be the case for ALK- or BRAF-positive NSCLC [18, 19]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.